Sareum Holdings plc (AIM:SAR)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 28.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.93M |
| Shares Out | 138.07M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,908 |
| Average Volume | 278,825 |
| Open | 20.77 |
| Previous Close | 21.00 |
| Day's Range | 20.10 - 22.00 |
| 52-Week Range | 9.50 - 29.00 |
| Beta | -0.96 |
| RSI | 62.80 |
| Earnings Date | Jun 10, 2026 |
About Sareum Holdings
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinic... [Read more]
Financial Performance
Financial StatementsNews
Sareum Holdings PLC (STU:RYH0) Half Year 2026 Earnings Call Highlights: Advancing Pipeline ...
Sareum Holdings PLC (STU:RYH0) Half Year 2026 Earnings Call Highlights: Advancing Pipeline Amidst Challenges
Half Year 2026 Sareum Holdings PLC Earnings Call Transcript
Half Year 2026 Sareum Holdings PLC Earnings Call Transcript
Sareum Holdings Earnings Call Transcript: H1 2026
Interim results show stable expenses, a GBP 1.65m loss, and GBP 2.5m cash. 1801 advances toward phase II, 1802 is prepped for licensing, and SRA737 is actively marketed with extended IP. CNS and business development efforts are progressing.
Sareum Holdings Transcript: AGM 2025
The meeting covered operational progress, financials, and strategic plans, with all resolutions passed by strong majorities. SDC-1801 advances toward phase II, while SRA737 and SDC-1802 are prioritized for partnering. Shareholders raised concerns about communication, funding, and board share purchases.
Full Year 2025 Sareum Holdings PLC Live Presentation Transcript
Full Year 2025 Sareum Holdings PLC Live Presentation Transcript
Sareum Holdings Earnings Call Transcript: H2 2025
Pipeline progress continues with a focus on STC-1801, despite a toxicology study setback unrelated to the drug. Operating loss narrowed to under £3 million, with £3.5 million in cash, and partnering remains key for late-stage development.
Sareum Holdings Earnings Call Transcript: H1 2025
Regained control of SRA737, expanded the clinical pipeline, and completed a positive phase I trial for SDC-1801. Operating expenses and losses decreased year-over-year, with a strong cash position supporting ongoing development and active licensing discussions.
Sareum Holdings Transcript: AGM 2024
All AGM resolutions were passed, including director re-elections and share authorities. The board highlighted the completion of a key clinical study, outlined plans for advancing pipeline assets, and addressed questions on strategy, partnerships, and data disclosure.
Sareum Holdings Earnings Call Transcript: H2 2024
Completed a successful Phase 1 trial for SDC-1801 with strong safety and efficacy data, raised £4.4 million to fund Phase 2 readiness, and awaits milestone updates on SRA737. Operating loss increased due to higher clinical trial costs, and the company remains open to partnering or advancing independently.